EDF Health

Selected tag(s): Endocrine disruption

April brings showers…and a flurry of new studies on the risks of perfluorinated chemicals

By Rachel Shaffer / Published: April 30, 2013

Rachel Shaffer is a research assistant.

What do waterproof jackets, car wax, and non-stick pans have in common?

Aside from being great Father’s Day presents (Dad, I’m thinking ahead this year!), they also all are made with perfluorinated compounds, or PFCs. There are hundreds of different PFCs, and their oil- and water-resistant properties make them useful in a variety of products, from cookware and carpets to food-packaging and electronics.  

Unfortunately, these chemicals have less desirable properties as well. Thanks to their strong molecular bonds, PFCs do not readily break down; they persist in the environment and in our bodies. And, widespread use has led to extensive human exposure. The Centers for Disease Control’s (CDC) human biomonitoring program, the National Health and Nutrition Examination Survey (NHANES), detected four types of PFCs in over 98% of samples representative of the U.S. population collected in 2003-2004.  

Two of the compounds detected in NHANES, perfluorooctane sulfonic acid (PFOS) and perfluorootanoic acid (PFOA), are the focus of three new studies published this month in Environmental Health Perspectives. These studies, one reporting an association with osteoarthritis in women, another an association with semen quality in men, and a third an association with asthma in children, add to a growing concern about the potential adverse effects of these ubiquitous chemicals.

What follows is a brief overview of the findings of these new studies.  Read More »

Posted in Emerging science, Health policy, Health science / Also tagged | Comments are closed

Prevention as cure: Confronting the environmental contributions to breast cancer

By Sarah Vogel / Published: February 19, 2013

Sarah Vogel, Ph.D., is Managing Director of EDF’s Health Program.

Breast cancer is a personal issue for too many of us.  For six years I have watched the disease overtake a very dear friend’s life.  First diagnosed at 32, she underwent radical treatments— surgeries, radiation and chemo— and three years later faced metastatic breast cancer that is now ravaging her body. 

She is one of the three million women in the U.S. currently facing, or who have been treated for, for breast cancer.  She is also one of a growing number of women under 50 getting the disease with no family history of breast cancer. 

Many women today live longer with or after the disease due to remarkable advancements in medicine, but treatment is not a path anyone would choose.  It takes a heavy emotional and physical toll, and often comes with serious impacts on a women’s life, such as the loss of fertility and the risk of reoccurrence.  Medical costs for treatment of breast cancer totaled $17.35 billion in 2012. And even with advances in treatment, in 2012, more than 40,000 women died from the disease.  

The question every woman must ask is: “What can I do to prevent the disease for myself or my daughter?” Read More »

Posted in Health policy, Health science, TSCA reform / Also tagged , | Comments are closed

21st Century on the horizon for endocrine disruptor screening?

By Rachel Shaffer / Published: January 31, 2013

Rachel Shaffer is a research assistant. Jennifer McPartland, Ph.D., is a Health Scientist.

BPA, DDT, PCBs, PBDEs, phthalates, PFOA … Forgive the alphabet soup, but chances are you’ve heard of at least some of these endocrine-disrupting chemicals (EDCs), which have been the subject of a lot of public and media attention in the last several years. Research has begun to uncover the ways in which these chemicals can interact with the body’s hormone – or endocrine – system to disrupt various natural biological processes, including metabolism, the reproductive system, and development of the brain and nervous systems.

While the endocrine-disrupting properties of the chemicals named above have been confirmed, scientists suspect there may be many more such chemicals in our environment, in the products we use, and in our bodies.  How can we identify them?

Legislation enacted in 1996 required the U.S. Environmental Protection Agency (EPA) to develop a screening program to identify potential EDCs.  More than 10 years later, EPA finally launched the Endocrine Disruptor Screening Program (EDSP).  Testing is being conducted in two phases, or “tiers.”  In “Tier 1,” a screening battery of validated in vivo and in vitro assays is used to identify chemicals with potential to interfere with the endocrine system. Chemicals flagged in the first tier of testing are then subject to “Tier 2” testing intended to determine the specific effect and the lowest dose at which it occurs. (We should note this program is very controversial and the subject of ongoing debate, but that is not the subject of this post.)

EPA has identified an estimated 9,700 chemicals to be screened – a very daunting task given the time- and resource-intensive nature of the testing battery EPA has established.  Might there be a way to expedite the identification and testing of the more problematic chemicals? A study published earlier this year in Environmental Health Perspectives (EHP) investigates a possible approach: using in vitro high-throughput (HT) assays developed through EPA’s ToxCast and Tox21 programs to target and prioritize chemicals for further testing under the EDSP. While use of these assays poses its own challenges, might it at least help in determining an appropriate testing sequence?  Read More »

Posted in Emerging testing methods, Health science / Also tagged , , , , , , , | Comments are closed

ECHA raises its sights: Several recent additions to the REACH Candidate List set precedents

By / Published: January 29, 2013

Alissa Sasso is a Chemicals Policy Fellow.

The European Union is maintaining a steady pace as it works to address chemicals of concern: Last month, the European Chemicals Agency (ECHA) added 54 Substances of Very High Concern (SVHCs) to the Candidate List for Authorisation under its REACH Regulation, bringing the total number of substances on the list to 138. ECHA posted a press release listing the new SVHCs and describing some of the more interesting additions, which we’ve highlighted below.

For 23 of the additions, REACH’s Member State Committee (MSC) reviewed public comments during the comment period on draft SVHC proposals before voting unanimously to add all of them onto the Candidate List. The other 31 new additions were not challenged during the public comment period, and hence moved directly onto the candidate list without MSC consultation.

The majority of the new SVHCs, like most substances already on the list, are classified as carcinogen, mutagenic and/or toxic to reproduction (CMRs).  But it’s with the other new listings that it gets really interesting.  Read More »

Posted in EU REACH, Health policy / Also tagged , , | Comments are closed

EDF launches website on EPA’s emerging chemical testing programs

By Jennifer McPartland / Published: November 12, 2012

Jennifer McPartland, Ph.D., is a Health Scientist.

New approaches for evaluating chemical hazard and risk are needed to help address substantial data gaps that exist for the thousands of chemicals currently in the marketplace as well as those yet to be introduced.   EPA has been investing significant resources to create research programs dedicated to advancing new types of chemical testing and assessment approaches.  But what exactly are these approaches?  How might they improve the practice of risk assessment?  Are they appropriate for decision-making, and if so, what kinds of decision making?  What role does the public interest community have to play? 

To explore these and other important issues, EDF’s Health Program has launched a website, “Chemical Testing in the 21st Century,” that provides an  introduction to these new approaches and the programs the EPA has built around them—including their potential uses, benefits and limitations.  The website includes the following informational resources: 

  1. Chemical Testing in the 21st Century: A Primer – An introduction to EPA’s Computational Toxicology (CompTox) research initiative and its component programs, such as ToxCast; a discussion of the opportunities and challenges of these new testing programs; and a discussion of issues and needs for greater engagement by the public interest community.  
  2. Chemical Testing in the 21st Century: Webinar Series – Linked audio and video recordings of each of EDF’s three webinars (held in October) featuring EDF and EPA scientists exploring the basics of EPA’s new testing programs and the promises and challenges they present. 

We will soon be adding a page with descriptions of and links to additional resources.

Posted in Emerging testing methods, Health science / Also tagged , , , , , , , | Comments are closed

Still looking for a moment of truth from ACC

By Richard Denison / Published: September 11, 2012

Richard Denison, Ph.D., is a Senior Scientist.

We’ve blogged here recently about how the American Chemistry Council (ACC) is seeking to hide the truth about the major changes made to the Safe Chemicals Act.  And about its efforts to suppress the truth about chemicals linked to cancer.  But its tenuous relationship with the truth doesn’t end there.  Read More »

Posted in Health policy, TSCA reform / Also tagged , , , | Read 1 Response